- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.03. | CARSGEN-B (02171): GRANT OF OPTIONS PURSUANT TO THE POST-IPO SHARE OPTION SCHEME; AND GRANT OF RSUS PURSUANT TO THE 2019 EQUITY INCENTIVE PLAN | 1 | HKEx | ||
| 09.03. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - INCLUSION IN THE STOCK LIST UNDER THE SOUTHBOUND STOCK CONNECT | 1 | HKEx | ||
| 06.03. | CARsgen Therapeutics Announces 2025 Annual Results | 242 | PR Newswire | SHANGHAI, March 6, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, has announced its... ► Artikel lesen | |
| 06.03. | CARSGEN-B (02171): ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2025 AND PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND THE ... | - | HKEx | ||
| CARSGEN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 24.02. | CARSGEN-B (02171): DATE OF BOARD MEETING | 1 | HKEx | ||
| 13.02. | CARsgen to Expand Commercial Manufacturing Base in Shanghai | 1 | Contract Pharma | ||
| 13.02. | CARsgen Therapeutics: CARsgen Signs Strategic Cooperation Agreements to Expand CAR-T Commercial Manufacturing Base in Jinshan, Shanghai | 163 | PR Newswire | SHANGHAI, Feb. 12, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies... ► Artikel lesen | |
| 13.02. | CARSGEN-B (02171): DISCLOSABLE TRANSACTION - ENTERING INTO THE STRATEGIC COOPERATION AGREEMENTS | 1 | HKEx | ||
| 26.01. | CARSGEN-B (02171): PROFIT ALERT - ESTIMATED REDUCTION IN LOSS | 2 | HKEx | ||
| 23.01. | CARSGEN-B (02171): (REVISED) NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 23.12.25 | CARSGEN-B (02171): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 18.12.25 | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - SHARE REPURCHASE BY THE COMPANY AND SHAREHOLDING INCREASE BY THE SUBSTANTIAL SHAREHOLDER | 2 | HKEx | ||
| 11.12.25 | CARSGEN-B (02171): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 08.12.25 | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - UPDATED RESEARCH RESULTS ON CT0596 AT ASH 2025 ANNUAL CONGRESS | 1 | HKEx | ||
| 01.12.25 | CARSGEN-B (02171): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 17.11.25 | CARSGEN-B (02171): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 13.11.25 | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - SHARE REPURCHASE BY THE COMPANY AND SHAREHOLDING INCREASE BY THE SUBSTANTIAL SHAREHOLDER | - | HKEx | ||
| 06.11.25 | CARSGEN-B (02171): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 03.11.25 | CARsgen Therapeutics: CARsgen Announces Positive Clinical Data for Allogeneic CAR-T Products CT0596 and CT1190B | 161 | PR Newswire | SHANGHAI, Nov. 3, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies... ► Artikel lesen | |
| 21.10.25 | CARSGEN-B (02171): NEXT DAY DISCLOSURE RETURN | 2 | HKEx |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 34,290 | -2,89 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| EVOTEC | 4,470 | -0,73 % | Evotec-Aktie: Neuzugang könnte neue Hoffnungen wecken | Die Evotec-Aktie blieb in der schwachen Phase der Börsen stabil und konnte sich entgegen dem Trend leicht erholen. Am Donnerstag ging sie mit einem Gewinn von +2,2% aus dem Handel und steht bei rund... ► Artikel lesen | |
| CG ONCOLOGY | 69,85 | +3,34 % | H.C. Wainwright hebt Kursziel für CG Oncology auf 100 US-Dollar an | ||
| ARCELLX | 114,80 | +0,05 % | Gilead extends Arcellx tender offer deadline to April 24 | ||
| BIONTECH | 77,20 | -2,40 % | BioNTech vs. Bioxyne: Wenn Forschungs-Riesen pausieren und Small Caps die Prognosen anheben | ||
| ERASCA | 17,060 | -0,35 % | Erasca, Inc.: Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results | Encouraging early clinical activity observed during ERAS-0015 dose escalation, including ongoing responses across multiple RAS-mutant tumors with favorable safety, tolerability, and pharmacokinetics... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 43,190 | 0,00 % | Enliven Therapeutics, Inc.: Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones | Cumulative major molecular response (MMR) rate of 69% by 24 weeks, with 53% of patients achieving MMR by 24 weeks in ongoing randomized Phase 1b cohorts
ELVN-001... ► Artikel lesen | |
| NUVALENT | 102,35 | -1,38 % | Nuvalent, Inc.: Nuvalent Announces Submission of New Drug Application to FDA for Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC | New Drug Application (NDA) based on data in TKI pre-treated patients from the global ALKOVE-1 Phase 1/2 clinical trial
CAMBRIDGE, Mass., April 7, 2026 /PRNewswire/... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 54,82 | 0,00 % | What's Going On With Structure Therapeutics Stock On Wednesday? | ||
| MINERALYS THERAPEUTICS | 28,300 | +0,18 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer | RADNOR, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities... ► Artikel lesen | |
| COGENT BIOSCIENCES | 35,610 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST) | Bezuclastinib NDA submitted under the FDA's RTOR program based on positive results from Phase 3 PEAK trial; bezuclastinib previously granted Breakthrough Therapy Designation in GISTBezuclastinib combination... ► Artikel lesen | |
| TYRA BIOSCIENCES | 37,680 | -3,14 % | Tyra Biosciences, Inc. - 8-K, Current Report | ||
| RELAY THERAPEUTICS | 13,490 | 0,00 % | Healthcare quant check: RLAY and TNGX lead Seeking Alpha's top picks ahead of Q1 earnings | ||
| VERA THERAPEUTICS | 40,060 | 0,00 % | Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer | BRISBANE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 307,30 | -0,66 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy | Elsunersen demonstrated placebo-adjusted seizure reduction from baseline of 77% (p=0.015) 71% of elsunersen-treated patients achieved >50% seizure reduction by period 6, with sustained benefit observed... ► Artikel lesen |
CARSGEN THERAPEUTICS HOLDINGS LTD gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CARSGEN THERAPEUTICS HOLDINGS LTD finden Sie auf Wallstreet Online.